Form 4: Akero Therapeutics COO Jonathan Young Reports Stock Sale to Cover Tax Obligations

Akero Therapeutics' Chief Operating Officer, Jonathan Young, reported the sale of 568 shares of common stock to cover tax withholding obligations related to vesting restricted stock units.

Summary

• Jonathan Young, the Chief Operating Officer of Akero Therapeutics, reported a transaction involving the company's common stock.
• On September 10, 2024, Young sold 568 shares at a price of $26.18 per share.
• This sale was to cover tax withholding obligations related to the vesting of restricted stock units, as per the company's 'sell-to-cover' policy.
• Following the transaction, Young directly owns 236,286 shares of Akero Therapeutics common stock.
• Young also has indirect ownership of 20,000 shares each through three irrevocable trusts (EA Irrevocable Trust, CM Irrevocable Trust, and JL Irrevocable Trust) for the benefit of his children, for which his spouse is the trustee.
• Young disclaims beneficial ownership of the shares held in the irrevocable trusts.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports a routine stock sale to cover tax obligations. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders, like officers and directors, trade their company's stock. These filings provide transparency into insider transactions and can be monitored by investors for insights into management's perspective on the company's value and prospects.

Stakeholder Impact

• The stock sale may have a minor impact on shareholders due to the small number of shares involved.
• The 'sell-to-cover' policy ensures that the company meets its tax obligations related to employee compensation.

Key Dates